| Literature DB >> 32899437 |
Diogo Pinto1, Andréa Marques2,3, Joana F Pereira4, Paulo J Palma4,5, João Miguel Santos4,5.
Abstract
Background and objectives: The long-term outcome of endodontic microsurgery (EMS) performed on root-filled teeth affected by post-treatment apical periodontitis (AP) has been a matter of debate, re-launched by the introduction of novel root-end filling materials which have been proven to improve the short-term outcome of EMS. The purpose of this systematic review and meta-analysis is to evaluate the clinical and radiographic long-term outcome of endodontic microsurgery in teeth diagnosed with secondary AP through radiographic evaluation. Materials andEntities:
Keywords: endodontic microsurgery; endoscope; root canal therapy; surgical endodontic retreatment; survival rate; systematic review; treatment outcome
Mesh:
Substances:
Year: 2020 PMID: 32899437 PMCID: PMC7558840 DOI: 10.3390/medicina56090447
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Figure 1Flowchart of the article selection method according to The PRISMA Statement [35]. PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Studies included in the review and the success rate.
| Study | Design | No. of Teeth | Follow-Up (Years) | Root-End Filling | Recall Rate (%) | Success | Overall | Survival Rate * |
|---|---|---|---|---|---|---|---|---|
| Truschnegg et al., 2020 [ | PCS | 87 | 10 to 13 | IRM | 71% | N.A. | 76% | 79% |
| von Arx et al., 2019 [ | PCS | 195 | 10 | ProRoot® MTA grey | 61% | ProRoot® MTA grey | 82% | 88% |
| ProRoot® MTA white | ProRoot® MTA white | |||||||
| Kim et al., 2016 [ | RCT | 260 | 4 | ProRoot® MTA | 70% | ProRoot® MTA | 91% | 92% |
| Super EBA | Super EBA | |||||||
| Caliskan et al., 2016 [ | PCS | 103 | 2 to 6 | ProRoot® MTA | 87% | N.A. | 80% | 100% |
| Tawil et al., 2015 [ | PCS | 155 | 3 | ProRoot® MTA grey or SuperEBA | 82% | N.A. | 69% | 100% |
| von Arx et al., 2014 [ | PCS | 339 | 5 | ProRoot MTA® | 80% | ProRoot MTA® | 85% | 89% |
| COMP | COMP | |||||||
| Song et al., 2012 [ | RCT | 172 | 6 to 10 | IRM, Super EBA or ProRoot® MTA | 61% | N.A. | 93% | 100% |
| von Arx et al., 2012 [ | PCS | 191 | 5 | ProRoot MTA® ( | 88% | ProRoot MTA® | 76% | 93% |
| SuperEBA | SuperEBA | |||||||
| Retroplast ( | Retroplast | |||||||
| Taschieri et al., 2008 [ | RCT | 113 | 2 | SuperEBA ( | 89% | N.A. | 92% | 100% |
| Chong et al., 2003 [ | RCT | 183 | 2 | MTA ( | 59% | MTA | 90% | 100% |
| IRM ( | IRM |
Prospective clinical study (PCS), Randomized clinical trial (RCT), not available (N.A.), zinc oxide-eugenol intermediate restorative cement (IRM), mineral trioxide aggregate (MTA), dentin-bonded adhesive resin composite (COMP), Super ethoxybenzoic acid (SuperEBA). * rate not reported in the articles, calculated based on available values.
Data summary of the included studies analysis.
| Study | Study Design | Material | Evaluated Parameters | Follow-up (years) | Sample Size | Previous Treatments | Success Rate (%) | Recall Rate (%) | Results: Prognostic Factors | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. Patients | No. Teeth | No. Re-Surgery | No. NSER | Clinical | Radiographic | ||||||||
| Healed | Non-Healed | ||||||||||||
| Truschnegg et al., 2020 [ | PCS | IRM | 1. Age | 10 to 13 | 73 | 87 | 19 | 0 | 79 | 76 | 24 | 71 | No significant differences: Age, sex, alcohol habits, tooth location, previous endodontic surgery, size of the pre and postoperative lesion, or perioperative antibiotics. |
| von Arx et al., 2019 [ | PCS | ProRoot® MTA Grey or ProRoot® MTA White | 1. Sex | 10 | NA | 119 | 12 | NA | NA | Overall rate: 82 | Overall rate: 18 | 61 | No significant differences: Age, sex, type of MTA, or first-time versus repeat surgery. |
| Kim et al., 2016 [ | RCT | ProRoot® MTA, Super EBA | 1. Type of material | 4 | NA | 260 | NA | NA | NA | Overall rate: 91 | Overall rate: 9 | 70 | No significant differences: Type of material. |
| Caliskan et al., 2016 [ | PCS | ProRoot® MTA | 1. Sex | 2 to 6 | 108 | 108 | 18 | 42 | NA | 80 | 20 | 87 | No significant differences: Sex, age, tooth location and type, quality of the root canal filling, presence or absence of a post, previous endodontic treatment or retreatment, previous nonsurgical or surgical endodontic treatment, size and histopathology of periapical lesions, antibiotic therapy, or postoperative healing course. |
| Tawil et al., 2015 [ | PCS | ProRoot® MTA grey or SuperEBA | 1. Sex | 3 | NA | 155 | NA | NA | NA | Overall rate: 69 | Overall rate: 31 | 82 | No significant differences: Sex, Age, Tooth location, or root-end filling material (Super EBA vs. MTA) Significant differences: Presence of dentinal defect (lower success rate) |
| von Arx et al., 2014 [ | PCS | ProRoot® MTA, dentin-bonded adhesive resin composite (COMP) | 1. Type of material (MTA or COMP) | 5 | 339 | 339 | 31 | NA | NA | Overall rate:85 MTA Group: 93 | Overall rate:15 MTA Group: 7 | 80 | No significant differences: Age, sex, type of tooth treated, presence of post/screw, or type of surgery (first-time vs. repeated surgery). Significant differences: Type of material (higher success rate for MTA treated teeth) |
| Song et al., 2012 [ | RCT | IRM, Super EBA, ProRoot® MTA | 1. Age | 6 to 10 | NA | 172 | NA | NA | NA | 93 | 7 | 61 | NA |
| von Arx et al., 2012 [ | PCS | SuperEBA, ProRoot® MTA, Retroplast | 1. Patient-related (i.e., age, sex, and smoking) | 5 | 194 | 194 | 16 | NA | 85 | Overall rate:76 ProRoot® MTA Group: 88 SuperEBA Group: 67 Retroplast Group: 75 | Overall rate: 24 ProRoot® MTA Group: 12SuperEBA Group: 33 Retroplast Group: 25 | 88 | No significant differences: Patient related factors, tooth related factors (i.e., tooth type, pain, clinical signs/symptoms, size of periapical lesion, apical extent of root canal filling, post, and previous apical surgery), or treatment related factors (i.e., antibiotic prescription, and initial postoperative healing). |
| Taschieri et al., 2008 [ | RCT | SuperEBA | 1. Type of magnification device (microscope vs. endoscope) | 2 | 70 | 113 | NA | 113 | NA | 92 | 8 | 89 | No significant differences: Type of magnification device (microscope vs. endoscope), or tooth location (arch) |
| Chong et al., 2003 [ | RCT | MTA (developed at Loma Linda University, California), IRM | 1. Type of material (MTA or IRM) | 2 | 183 | 183 | NA | NA | NA | Overall rate: 90 MTA Group: 92 IRM Group: 87 | Overall rate:10 MTA Group: 8 IRM Group: 13 | 59 | No significant differences: Type of material |
Prospective clinical study (PCS), Randomized clinical trial (RCT), not available (N.A.), zinc oxide-eugenol intermediate restorative cement (IRM), mineral trioxide aggregate (MTA), dentin-bonded adhesive resin composite (COMP), Super ethoxybenzoic acid (SuperEBA).
Figure 2Risk of bias summary of the included randomized clinical trials (RCTs).
Risk of bias summary of the included prospective clinical studies (PCSs).
| Domains | ||||||||
|---|---|---|---|---|---|---|---|---|
| Pre intervention | At intervention | Post intervention | ||||||
|
| Bias due to Confounding | Bias in Selecting Participants for the Study | Bias in Classifying Interventions | Bias due to Deviations from Intended Intervention | Bias due to Missing Data | Bias in Measuring Outcomes | Bias in Selecting Reported Result | Overall RcB Judgment |
|
| Moderate | Low | Low | Low | Low | Low | Low | Low |
|
| Low | Low | Low | Low | Low | Low | Low | Low |
|
| Moderate | Low | Low | Low | Low | Moderate | Low | Low |
|
| Low | Low | Low | Low | Low | Moderate | Moderate | Low |
|
| Low | Low | Low | Low | Low | Moderate | Low | Low |
|
| Low | Low | Low | Low | Low | Low | Low | Low |
Figure 3Forest plot of recall rate for randomized clinical trials (RCTs).
Figure 4Forest plot of recall rate for prospective clinical studies (PCSs).
Figure 5Forest plot of success rate outcome for randomized clinical trials (RCTs).
Figure 6Forest plot of success rate outcome for prospective clinical studies (PCSs).